Loading
Yanuki
KEYWORD TOPIC
VOQUEZNA® Receives 10-Year Exclusivity Extension from FDA | VOQUEZNA® Receives 10-Year Exclusivity Extension from FDA

Health / Pharmaceuticals

VOQUEZNA® Receives 10-Year Exclusivity Extension from FDA

Phathom Pharmaceuticals (Nasdaq: PHAT) announced that the FDA has approved its Citizen Petition, granting VOQUEZNA® (vonoprazan) tablets 10 years of New Chemical Entity exclusivity, extending until May 3, 2032. This decision corrects the Or...

Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets through May 3, 2032
VOQUEZNA® Receives 10-Year Exclusivity Extension from FDA Image via Yahoo Finance
TOPIC phat stock